| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 910 | 2016 |
| RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer R Wang, H Hu, Y Pan, Y Li, T Ye, C Li, X Luo, L Wang, H Li, Y Zhang, F Li, ... Journal of clinical oncology 30 (35), 4352-4359, 2012 | 625 | 2012 |
| The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies MJ Niederst, H Hu, HE Mulvey, EL Lockerman, AR Garcia, Z Piotrowska, ... Clinical Cancer Research 21 (17), 3924-3933, 2015 | 554 | 2015 |
| Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Y Zhang, L Wang, Y Li, Y Pan, R Wang, H Hu, H Li, X Luo, T Ye, Y Sun, ... OncoTargets and therapy, 567-573, 2014 | 252 | 2014 |
| ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features Y Pan, Y Zhang, Y Li, H Hu, L Wang, H Li, R Wang, T Ye, X Luo, Y Zhang, ... Lung cancer 84 (2), 121-126, 2014 | 232 | 2014 |
| Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis Y Zhang, Y Sun, Y Pan, C Li, L Shen, Y Li, X Luo, T Ye, R Wang, H Hu, ... Clinical cancer research 18 (7), 1947-1953, 2012 | 190 | 2012 |
| PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup L Wang, H Hu, Y Pan, R Wang, Y Li, L Shen, Y Yu, H Li, D Cai, Y Sun, ... PloS one 9 (2), e88291, 2014 | 186 | 2014 |
| FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non–small cell lung cancer R Wang, L Wang, Y Li, H Hu, L Shen, X Shen, Y Pan, T Ye, Y Zhang, ... Clinical Cancer Research 20 (15), 4107-4114, 2014 | 150 | 2014 |
| Genomic and immune profiling of pre-invasive lung adenocarcinoma H Chen, J Carrot-Zhang, Y Zhao, H Hu, SS Freeman, S Yu, G Ha, ... Nature communications 10 (1), 5472, 2019 | 144 | 2019 |
| Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose H Li, Y Pan, Y Li, C Li, R Wang, H Hu, Y Zhang, T Ye, L Wang, L Shen, ... Lung Cancer 79 (1), 8-13, 2013 | 134 | 2013 |
| Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms H Hu, Z Piotrowska, PJ Hare, H Chen, HE Mulvey, A Mayfield, S Noeen, ... Cancer Cell 39 (11), 1531-1547. e10, 2021 | 127 | 2021 |
| The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers R Wang, Y Pan, C Li, H Hu, Y Zhang, H Li, X Luo, J Zhang, Z Fang, Y Li, ... Clinical Cancer Research 18 (17), 4725-4732, 2012 | 110 | 2012 |
| Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains C Li, Y Sun, R Fang, X Han, X Luo, R Wang, Y Pan, H Hu, Y Zhang, ... Journal of Thoracic Oncology 7 (1), 85-89, 2012 | 109 | 2012 |
| MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer D Zheng, R Wang, T Ye, S Yu, H Hu, X Shen, Y Li, H Ji, Y Sun, H Chen Oncotarget 7 (27), 41691, 2016 | 89 | 2016 |
| Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer Y Liu, X Luo, H Hu, R Wang, Y Sun, R Zeng, H Chen PloS one 7 (12), e51748, 2012 | 86 | 2012 |
| Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM KA Song, MJ Niederst, TL Lochmann, AN Hata, H Kitai, J Ham, KV Floros, ... Clinical Cancer Research 24 (1), 197-208, 2018 | 84 | 2018 |
| Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients R Wang, Y Zhang, Y Pan, Y Li, H Hu, D Cai, H Li, T Ye, X Luo, Y Zhang, ... Oncotarget 6 (33), 34300, 2015 | 83 | 2015 |
| A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component Y Zhang, R Wang, D Cai, Y Li, Y Pan, H Hu, L Wang, H Li, T Ye, X Luo, ... Journal of thoracic oncology 9 (12), 1772-1778, 2014 | 78 | 2014 |
| Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience B Li, H Chen, J Xiang, Y Zhang, C Li, H Hu, Y Zhang The Journal of thoracic and cardiovascular surgery 144 (4), 778-786, 2012 | 78 | 2012 |
| ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR Y Li, Y Pan, R Wang, Y Sun, H Hu, X Shen, Y Lu, L Shen, X Zhu, H Chen PLoS One 8 (7), e69016, 2013 | 76 | 2013 |
